Please assess the completion status of the following clinical trial:

Trial Title: Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria - Patients must meet all of the following criteria:~* \> 18 and \< 85 years of age~* ICD implanted for primary prophylaxis against sudden cardiac death or ICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes~* Coronary artery disease (CAD) with prior myocardial infarction (MI)~* ICD or electrocardiogram (ECG) documentation of ventricular arrhythmia responsible for appropriate ICD therapy \[antitachycardia pacing (ATP) \& shocks\].~Exclusion Criteria - Patients should not have any of the following criteria:~* Contraindication or allergy to contrast media, routine procedural medications or catheter materials~* Contraindication to an interventional procedure~* Current or previous (within 3 months) amiodarone therapy~* Atrial Fibrillation requiring antiarrhythmic drug therapy~* Contraindication to amiodarone therapy~* New York Heart Association (NYHA) functional class IV~* Myocardial infarction within the past 60 days~* Stroke within the past 90 days~* Unstable angina~* Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or long QT syndrome~* Patients with active ischemia that are eligible for revascularization~* Life expectancy less than 6 months~* Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation~* Untreated hypothyroidism or hyperthyroidism. Patients who are euthyroid on thyroid hormone replacement therapy are acceptable.~* Current enrollment in another investigational drug or device study.~* Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the patient for the entire study period.~* Absolute contra-indication to the use of heparin and or warfarin.~* Documented intra-atrial thrombus, ventricular thrombus (\< 6 months after detection of thrombus), tumor, or another abnormality which precludes catheter introduction.~* Females of childbearing potential who are not practicing protocol acceptable method of birth control.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Ablation (Type: ACTIVE_COMPARATOR): Catheter based radiofrequency ablation for ischemic ventricular tachycardia
- Amiodarone (Type: ACTIVE_COMPARATOR): amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).